top of page

oncoMonitor

Molecular test

for detection of cancer progression and treatment monitoring

Biotechnology company Elphogene Inc., which has been founded as a spin-off

from the Genomac Research Institute in Prague, presents the oncoMonitor project

for monitoring of circulating tumor DNA (referred to as ctDNA)

in cancer patients.

About us

The Prague-based biotechnological start-up Elphogene has received an initial investment from i&i Prague in order to implement its oncoMonitor, a liquid biopsy technology into a commercial assay for non-invasive diagnostic monitoring of patients in advanced stages colorectal cancer.

The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute.

Results & Experiences

We have been investigating ctDNA from patients' blood since 2009. We gained experience with patients with various types of cancer (lungs, pancreas, stomach, head and neck), but we found out the best application for colorectal cancer patients for whom oncoMonitor was primarily developed.

So far, in several extensive research studies, we have examined more than 500 such patients for the presence of ctDNA, and in at least 30 of them, we conducted long-term postoperative monitoring of ctDNA levels.

News & Media

AMP 2020 Annual Meeting & Expo - Nov 16 - 20, 2020

Clinical application of Elphogene oncoMonitor technology was presented at the AMP 2020 Annual Meeting & Expo of the Association for Molecular Pathology (AMP).

EACR Conference on Liquid Biopsies - Virtual Event - Nov 18 - 19, 2020

Marek Minarik, Ph.D. presented the company Elphogene and the oncoMonitor test at the virtual conference of the European Association for Cancer Research.

17th postgraduate course SGO - News in the diagnosis and treatment of colorectal cancer - part 1 - Nov 5, 2020

Marek Minarik, Ph.D. presented a lecture at an online course organized by the Society for Gastrointestinal Oncology.

AACR Annual Meeting 2020 (Virtual Meeting II) - Jun 22 - 24, 2020

Marek Minarik, Ph.D. presented the company Elphogene and the oncoMonitor test at the annual conference of the American Association for Cancer Research.

PragueONCO - Jan 29 - 31, 2020

Marek Minarik, Ph.D. presented the company Elphogene and the oncoMonitor test at a multidisciplinary oncological congress in Prague, Czech Republic.

AACR Special Conference on Advances in Liquid Biopsies - Jan 13 - 16, 2020

Marek Minarik, Ph.D. presented the latest data from clinical trials using liquid biopsy based on oncoMonitor™ technology in patients with lung cancer at a conference in Miami, Florida, USA.

Published article in the World Journal of Gastroenterology - Dec 28, 2019

Researchers from Elphogene and the Genomac Research Institute, in collaboration with leading Czech oncology centers, have published an article in an international scientific journal.

Press release - Sep 23, 2020

Clinical application of Elphogene oncoMonitor technology will be presented at the AMP 2020 Annual Meeting & Expo of the Association for Molecular Pathology (AMP), which will be held virtually November 16-20.

Press release - Sep 10, 2020

Elphogene, s.r.o. received grant from the Technology Agency of the Czech Republic for the project “Sample prep system and technology for cancer testing by liquid biopsy”.

Report by CzechSight, s.r.o. - Jun 15, 2020

The report "Detection of cancer recurrence from blood collection is becoming common reality" about Elphogene, s.r.o. published by CzechSight, s.r.o.

Elphogene in the article of the Hospodářské noviny Journal - April 23, 2020

DNA helps diagnose cancer. The key is early detection.

bottom of page